S R Denmeade
Overview
Explore the profile of S R Denmeade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
698
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mandl A, Jasmine S, Krueger T, Kumar R, Coleman I, Dalrymple S, et al.
bioRxiv
. 2024 Feb;
PMID: 38328141
Statement Of Significance: Neuroendocrine prostate cancer presents a clinical challenge due to the lack of effective treatments. Our research demonstrates that bomedemstat, a potent and selective LSD1 inhibitor, effectively combats...
2.
Rogers O, Rosen D, Antony L, Harper H, Das D, Yang X, et al.
Sci Rep
. 2021 Jul;
11(1):14925.
PMID: 34290365
Prostate cancer cells are characterized by a remarkably low proliferative rate and the production of high levels of prostate-specific proteases. Protein-based toxins are attractive candidates for prostate cancer therapy because...
3.
Teply B, Luber B, Denmeade S, Antonarakis E
Prostate Cancer Prostatic Dis
. 2016 Feb;
19(1):72-8.
PMID: 26857146
Background: Prednisone and other corticosteroids can provide palliation and tumor responses in patients with prostate cancer. The combination of docetaxel and prednisone was the first treatment shown to prolong survival...
4.
Barakat D, Zhang J, Barberi T, Denmeade S, Friedman A, Paz-Priel I
Oncogene
. 2015 Mar;
34(48):5912-22.
PMID: 25772238
The processes associated with transition to castration-resistant prostate cancer (PC) growth are not well understood. Cellular senescence is a stable cell cycle arrest that occurs in response to sublethal stress....
5.
Paller C, Olatoye D, Xie S, Zhou X, Denmeade S, Eisenberger M, et al.
Prostate Cancer Prostatic Dis
. 2013 Oct;
17(1):28-33.
PMID: 24100642
Background: PSA doubling time (PSADT) is an attractive intermediate end point for assessing novel therapies in biochemically recurrent prostate cancer (BRPC). This study explores whether PSADT calculations are influenced by...
6.
Morris M, Eisenberger M, Pili R, Denmeade S, Rathkopf D, Slovin S, et al.
Ann Oncol
. 2012 May;
23(10):2714-2719.
PMID: 22553195
Background: This first-in-human phase I/IIA study was designed to evaluate the safety and pharmacokinetics (PKs) of AGS-PSCA a fully human monoclonal antibody directed to prostate stem cell antigen (PSCA) in...
7.
Weiss M, Vitolo M, Mohseni M, Rosen D, Denmeade S, Park B, et al.
Oncogene
. 2010 Jun;
29(33):4715-24.
PMID: 20562907
The TP53 tumor suppressor gene is the most commonly mutated gene in human cancers. To evaluate the biological and clinical relevance of p53 loss, human somatic cell gene targeting was...
8.
Singh P, Uzgare A, Litvinov I, Denmeade S, Isaacs J
Endocr Relat Cancer
. 2006 Sep;
13(3):653-66.
PMID: 16954423
Prostatic carcinogenesis is associated with changes in the androgen receptor (AR) axis converting it from a paracrine dependence upon stromal signaling to an autocrine-initiated signaling for proliferation and survival of...
9.
10.
Tombal B, Denmeade S, Isaacs J
Cell Death Differ
. 2002 Apr;
9(5):561-73.
PMID: 11973614
Many agents, such as the endoplasmic reticulum Ca(2+) ATPase inhibitor, thapsigargin, or the ionophore, ionomycin, induce apoptosis by transiently elevating [Ca(2+)](i). The role of [Ca(2+)](i) in apoptosis induced by agents...